Loading
ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signalling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity.
CIViC holds 1 clinical evidence item and 0 assertions across 3 variants, naming Imatinib and Dasatinib. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.89, animal model 0.26, genetic association 0.33, somatic mutation 0.83). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Invasive Breast Carcinoma, Endometrial Carcinoma.
In plain words · ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.
ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis.
No product in this corpus aims at ABL2 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ABL2: RNA low tissue specificity; no normal tissue stained high; highest cancer staining carcinoid (1 of 3 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Endometrial cancer, Lung cancer (all types), Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P42684; CIViC gene ABL2; IntOGen ABL2; Human Protein Atlas ABL2 tissue; Open Targets ENSG00000143322 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Kruh G.D. et al, Science, 1986, "A novel human gene closely related to the abl proto-oncogene". Source.
Sources: HGNC HGNC:77 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42684 (protein name, function text, keywords and locations (REST API)); CIViC gene ABL2 (1 evidence items, 0 assertions, 3 variants; diseases: Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000143322 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: skin cancer 0.52, breast cancer 0.57, lung cancer 0.53 (GraphQL API, CC0)); IntOGen ABL2 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signalling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. Location: Cytoplasm, cytoskeleton (UniProt). Locus 1q25.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ABL2" OR ABSTRACT:"ABL2" OR TITLE:"ABL proto-oncogene 2, non-receptor tyrosine kinase" OR ABSTRACT:"ABL proto-oncogene 2, non-receptor tyrosine kinase" OR TITLE:"Tyrosine-protein kinase ABL2" OR ABSTRACT:"Tyrosine-protein kinase ABL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ABL2, not a curated reading list.